Appendix 1—table 2. Anakinra as an independent protective factor from development of severe respiratory failure (SRF) by day 14 among patients treated with dexamethasone.
Univariate and multivariate (Cox forward conditional) models, for the anakinra with standard-of-care group (SOC) and parallel SOC comparators are presented. Only admission variables that differ significantly between patients who developed and those who did not develop SRF by day 14 are provided.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variable no. (%) | SRF (−) (N = 46) | SRF (+) (N = 53) | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Anakinra treatment, n (%) | 31 (67.4) | 21 (39.6) | 0.55 (0.32–0.97) | 0.038 | 0.56 (0.32–0.97) | 0.038 |
| Soluble uPAR, ng/ml, median (Q1–Q3) | 9.60 (7.2–12.6) | 11.6 (7.3–12.6) | 1.10 (1.00–1.20) | 0.030 | 1.97 (1.14–3.41) | 0.018 |
| Ferritin, ng/ml, median (Q1–Q3) | 593.0 (411.3–968.5) |
633.0 (412.0–968.0) |
1.00 (1.00–1.00) | 0.025 | ||
Abbreviations: CI: confidence interval; HR: hazard ratio; n: number; Q: quartile; SRF: severe respiratory failure; uPAR: urokinase-type plasminogen activator receptor.